<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P10492127A0914 In another study, intravenous administration of devazepide, a specific cholecystokinin-A receptor antagonist, at a dose of 0.1 mg/kg/hr was begun 15 min before postprandial saline intake and continued for 1 hr."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="225" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="62" end="86" Gene="cholecystokinin-A receptor"/></CAS>